Follow the Money to Medical Device & Diagnostic Opportunities
Spotlight on VENITI, Inc.
Follow the Money to Medical Device & Diagnostic Opportunities highlights a newly funded medical device or diagnostic company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
VENITI is a U.S. private company that develops devices for the management and treatment of venous insufficiency. It raised $25 million in a completion of a Series D venture capital investment as reported in the PharmSource Lead Sheet on September 15, 2016.
- VENITI was founded in January 2010
- Corporate Headquarters: St. Louis, MO
- Facility: Fremont, CA
- VENITI plans to use the proceeds to support clinical trials and regulatory filings for its VICI VENOUS STENT system and to expand product development and commercial operations.
Device: VICI VENOUS STENT ™
Development Phase: Pivotal studies
Medical Specialty: Cardiovascular/Vascular
Purpose: Device – Therapeutic/Interventional
Type: Implant – Stent
Description: A system comprised of an invasive stent implant and disposable delivery system for the treatment of iliofemoral venous obstruction
US – PMA planned
EU – CE Mark approval
US – IDE approval
Australia – TGA approval
Classification: US Class III
- March 2015: $17 million in a completed venture capital investment
- June 2013: $9.7 million in a completed venture capital investment
- March 2011: $13.5 million in a completed venture capital investment
Medical Device & Diagnostics Pipeline1
|Product Candidate||Indication||Medical Specialty||Purpose||Type||Status|
|Veni RF Plus ablation system||Varicose veins||Cardiovascular/
|VICI VENOUS STENT system||Iliofemoral venous obstruction||Cardiovascular/
|Implant – Stent||Pivotal Studies|
|VICI Verto venous stent system||Postthrombotic syndrome||Cardiovascular/
|Implant – Stent||Marketed/Launched|
|Vidi Vena Cava Filter||Stent retrieval||Cardiovascular/
Regulatory Approvals and Clearances
|Product Candidate||Region||Approval/Clearance||Year of Approval or Clearance|
|VICI Verto venous stent system||EU||CE Mark||2016|
|VICI VENOUS STENT system||US||IDE Approval||2014|
|Veni RF Plus ablation system||EU||CE Mark||2013|
|VICI VENOUS STENT system||EU||CE Mark||2013|
|VICI VENOUS STENT system||Australia||TGA Approval||2013|
1Source: PharmSource Lead Sheet
|VENITI, Inc.||Key Officers|
|1610 Des Peres Road, Suite 385||Jeff Elkins, President & CEO|
|St. Louis, MA 63131 USA||Catherin Matthes, CFO|
|Phone: +1-855-994-4343||Stephen Kao, VP, R&D|
|Fax: +1-636-628-9991||Daniel Racinella, VP, Technology, Clinical Research & Regulatory Affairs|
|Web: www.veniti.com||Rodney Marcy, Chief Commercialization Officer|
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on CVRx, Inc.
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Avita Medical Ltd.
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Mainstay Medical International plc.